Clinical Research Directory
Browse clinical research sites, groups, and studies.
to Assess the Eradication Rate of 14-day Bismuth/Amoxicillin/PCAB Triple Therapy for the Treatment of Helicobacter Pylori Infection
Sponsor: Kaohsiung Medical University
Summary
To assess the efficacy and safety of 14-day bismuth/amoxicillin/PCAB triple therapy for the treatment of Helicobacter pylori infection in Taiwan
Official title: Efficacy of Bismuth/Amoxicillin/Potassium-competitive Acid Blocker Triple Therapy for the Treatment of Helicobacter Pylori Infection in Taiwan
Key Details
Gender
All
Age Range
18 Years - 80 Years
Study Type
INTERVENTIONAL
Enrollment
200
Start Date
2024-09-26
Completion Date
2026-01-31
Last Updated
2025-08-27
Healthy Volunteers
No
Conditions
Interventions
Bismuth amoxilillin potassium
vonoprazan 20mg， Twice a day amoxicillin 750mg，Four times a day tripotassium dicitrate bismuthate 300mg，Four times a day for 14 days
Locations (1)
Kaohsiung Medical University Hospital
Kaohsiung City, Taiwan